We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Kiwa Bio Tech Products Group Corporation (CE) | USOTC:KWBT | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.0002 | 0.00 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): March 4, 2020
Kiwa Bio-Tech Products Group Corporation
(Exact Name of Registrant as Specified in Charter)
Nevada | 000-33167 | 77-0632186 | ||
(State
or Other Jurisdiction
of Incorporation) |
(Commission
File Number) |
(IRS
Employer
Identification No.) |
3200
Guasti Road, Suite 100
Ontario, CA |
91761 | |
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (626) 715-5855
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol | Name of exchange on which registered | ||
Common Stock par value $0.001 | KWBT | OTCQB |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
[ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
[ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
[ ] | Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c) |
Item 5.02. Departure of Directors; Appointment of Directors.
On March 4, 2020, Yvonne Wang submitted her resignation as Chief Executive Officer, with immediate effect, however, will retainer position as a director of Kiwa Bio-Tech Products Group Corp.
On March 4, 2020, the Board of Directors appointed Mr. Wade Li as Chief Executive Officer of the Company with immediate effect. Mr. Li’s biography is as follows:
Wade Li (59)
Mr. Wade Li was one of the founders of Kiwa Bio-Tech Products Group Corporation in 1999. Previously, he was employed by the People’s Insurance Company of China. In 1989, he established Xinhua International Market Development Co., Ltd. and served as its President, investing in a variety of growth industries companies of high-tech, pharmaceutical, medical, real estate and related enterprises. He has extensive experience in corporate operation. Over the past two decades, Mr. Li has focused on China’s ecological agriculture industry, and accumulated significant experience in the field. He has also gained high recognition in the market and related government departments in microbial fertilizer, as well as the planning and promotion of green safe agricultural products.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
None
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: March 5, 2020
Kiwa Bio-Tech Products Group Corporation | ||
/s/ Wade Li | ||
By: | Wade Li | |
Title: | Chief Executive Officer |
1 Year Kiwa Bio Tech Products (CE) Chart |
1 Month Kiwa Bio Tech Products (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions